(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
This cafe takes orders in sign language. It's cherished by the Deaf community- Understanding Preschool Projects: An Extensive Aide
- Most loved Web-based feature: Which Stage Do You Like
- Are Saturn's rings made of a lost, shattered moon? New evidence arises for the case
- Step by step instructions to Look at Compact disc Rates: A Thorough Aide
- Pick Your Favored kind of salad
- Courageous Climbing: Trails and Stuff for Outside Lovers
- Andrew McCarthy's awe-inspiring image of a skydiver in front of the sun
- 9 African migrants died in freezing temperatures near Morocco-Algeria border
